Detalhe da pesquisa
1.
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med
; 384(13): 1216-1226, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33789010
2.
Glyoxylate reductase: Definitive identification in human liver mitochondria, its importance for the compartment-specific detoxification of glyoxylate.
J Inherit Metab Dis
; 47(2): 280-288, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38200664
3.
Genetic assessment in primary hyperoxaluria: why it matters.
Pediatr Nephrol
; 38(3): 625-634, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35695965
4.
The retinal phenotype in primary hyperoxaluria type 2 and 3.
Pediatr Nephrol
; 38(5): 1485-1490, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260161
5.
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria.
Kidney Int
; 101(3): 626-634, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34481803
6.
Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients.
J Am Soc Nephrol
; 32(12): 3175-3186, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34686543
7.
A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3.
Kidney Int
; 100(3): 621-635, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33865885
8.
Transplantation outcomes in patients with primary hyperoxaluria: a systematic review.
Pediatr Nephrol
; 36(8): 2217-2226, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33830344
9.
Development and Validation of a New Gas Chromatography-Tandem Mass Spectrometry Method for the Measurement of Enrichment of Glyoxylate Metabolism Analytes in Hyperoxaluria Patients Using a Stable Isotope Procedure.
Anal Chem
; 92(2): 1826-1832, 2020 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31867958
10.
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.
Kidney Int
; 96(6): 1389-1399, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685312
11.
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. Reply.
N Engl J Med
; 385(20): e69, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758265
12.
Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1.
Kidney Int
; 103(5): 990-993, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871948
13.
Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy.
Kidney Int
; 104(1): 203-204, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37349052
14.
Corrigendum to "Successful kidney-alone transplantation in a patient with PH1 on combination RNA-interference therapy." Kidney International, 2023;104:203-204.
Kidney Int
; 104(5): 1038, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37863627
15.
Plasma oxalate and glycolate concentrations in dialysis patients with and without primary hyperoxaluria type 1.
Nephrol Dial Transplant
; 38(7): 1773-1775, 2023 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898675
16.
Return-to-work in patients with acquired brain injury and psychiatric disorders as a comorbidity: A systematic review.
Brain Inj
; 29(5): 550-7, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25625788
17.
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope.
Nat Rev Nephrol
; 19(3): 194-211, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36604599
18.
Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium.
Kidney Int Rep
; 8(10): 2029-2042, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37849991
19.
Primary hyperoxaluria: the pediatric nephrologist's point of view.
Clin Kidney J
; 15(Suppl 1): i23-i28, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35592624
20.
Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry.
Kidney Int Rep
; 7(7): 1608-1618, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35812297